Skip to main content

Market Overview

Juno Therapeutics Signs $1 Billion Development Pact With Celgene


Juno Therapeutics Inc (NASDAQ: JUNO) soared Monday afternoon on news that it signed a 10-year drug development pact with Celgene Corporation (NASDAQ: CELG) after the bell Monday.

Under the agreement, Celgene will make an initial $1 billion payment to Juno in the form of $150 million in cash and the acquisition of 9.1 million Juno shares at $93 a piece.

Juno changed hands recently at $66.50, up $20.20 or 43 percent in the premarket.

Celgene also obtained the right to acquire up to a 30 percent stake in Juno during the 10-year agreement and will nominate a member to Juno's board.

Celgene gained an option in the deal to commercialize Juno programs outside North America while Juno said it will gain an option to co-develop and co-promote certain Celgene programs.

The deal concerns potential cancer and autoimmune disease treatments, with an initial focus on chimeric antigen receptor technology or Car-T, as well as T-cell receptor technologies.

Juno Chief Executive Hans E. Bishop called Celgene an ideal partner to "help us realize the full potential of our research while maintaining the independence we believe is so critical for true innovation."

Celgene has a market cap of $93.5 billion versus Juno's $4.14 billion.

Separately, Juno said it obtained approval to launch a Phase I trial of its non-Hodgkin lymphoma treatment.


Related Articles (CELG + JUNO)

View Comments and Join the Discussion!

Posted-In: News Health Care Contracts FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at